S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:MYGN

Myriad Genetics Stock Forecast, Price & News

$27.84
-0.59 (-2.08 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$26.76
Now: $27.84
$28.63
50-Day Range
$25.80
MA: $28.75
$31.34
52-Week Range
$9.24
Now: $27.84
$31.60
Volume569,228 shs
Average Volume893,033 shs
Market Capitalization$2.09 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.71
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Myriad Genetics logo

Headlines

A Preview Of Myriad Genetics's Earnings
February 22, 2021 |  finance.yahoo.com
New Study Favors Myriad Genetics' (MYGN) GeneSight Test
February 10, 2021 |  finance.yahoo.com
First Week of MYGN August 20th Options Trading
January 28, 2021 |  nasdaq.com
MYGN Jan 2021 8.000 call
January 16, 2021 |  uk.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MYGN
CUSIP62855J10
Phone801-584-3600
Employees2,700
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$638.60 million
Cash Flow$0.69 per share
Book Value$12.32 per share

Profitability

Net Income$-199,500,000.00

Miscellaneous

Market Cap$2.09 billion
Next Earnings Date5/4/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

0.99 out of 5 stars

Medical Sector

1051st out of 1,972 stocks

Diagnostic Substances Industry

19th out of 32 stocks

Analyst Opinion: 0.8Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$27.84
-0.59 (-2.08 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MYGN News and Ratings via Email

Sign-up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions

Is Myriad Genetics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 3 sell ratings and 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Myriad Genetics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares.
View analyst ratings for Myriad Genetics
or view top-rated stocks.

What stocks does MarketBeat like better than Myriad Genetics?

Wall Street analysts have given Myriad Genetics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Myriad Genetics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Myriad Genetics?

Myriad Genetics saw a decrease in short interest in February. As of February 12th, there was short interest totaling 5,040,000 shares, a decrease of 24.1% from the January 28th total of 6,640,000 shares. Based on an average trading volume of 845,000 shares, the days-to-cover ratio is presently 6.0 days. Approximately 7.0% of the shares of the stock are short sold.
View Myriad Genetics' Short Interest
.

When is Myriad Genetics' next earnings date?

Myriad Genetics is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Myriad Genetics
.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) announced its quarterly earnings data on Monday, February, 22nd. The company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). The firm had revenue of $154.60 million for the quarter, compared to analyst estimates of $148.11 million. Myriad Genetics had a negative trailing twelve-month return on equity of 4.07% and a negative net margin of 32.49%. The firm's revenue for the quarter was down 20.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.23 earnings per share.
View Myriad Genetics' earnings history
.

How has Myriad Genetics' stock price been impacted by Coronavirus (COVID-19)?

Myriad Genetics' stock was trading at $14.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MYGN stock has increased by 98.4% and is now trading at $27.84.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MYGN?

6 Wall Street analysts have issued twelve-month price objectives for Myriad Genetics' stock. Their forecasts range from $10.00 to $33.00. On average, they expect Myriad Genetics' stock price to reach $17.20 in the next twelve months. This suggests that the stock has a possible downside of 38.2%.
View analysts' price targets for Myriad Genetics
or view top-rated stocks among Wall Street analysts.

Who are Myriad Genetics' key executives?

Myriad Genetics' management team includes the following people:
  • Mr. R. Bryan Riggsbee, Exec. VP, CFO & Treasurer (Age 50, Pay $741.84k)
  • Dr. Jerry S. Lanchbury, Chief Scientific Officer (Age 62, Pay $632.04k)
  • Ms. Nicole Lambert, Group Pres of Myriad Oncology, Myriad Women's Health & Myriad International (Age 46, Pay $507.51k)
  • Mr. Paul J. Diaz, CEO, Pres & Director (Age 59)
  • Mr. Scott Gleason, Sr. VP of Investor Relations
  • Mr. Benjamin Jackson, Exec. VP, Gen. Counsel & Sec. (Age 42)
  • Dr. Clivetty Martinez, Chief Compliance Officer
  • Ms. Jayne Baird Hart, Exec. VP of HR (Age 61)
  • Mr. Paul Chip Parkinson, Exec. VP of Reimbursement Strategy
  • Mr. Mark S. Verratti, Pres of Myriad Neuroscience & Myriad Autoimmune (Age 53)

What is Paul Diaz's approval rating as Myriad Genetics' CEO?

12 employees have rated Myriad Genetics CEO Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among Myriad Genetics' employees.

Who are some of Myriad Genetics' key competitors?

What other stocks do shareholders of Myriad Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.62%), Dimensional Fund Advisors LP (3.67%), Morgan Stanley (2.96%), Northern Trust Corp (2.28%), New York State Common Retirement Fund (1.46%) and Bank of New York Mellon Corp (1.19%). Company insiders that own Myriad Genetics stock include Alexander Ford, Bernard Tobin, Gary A King, Jerry S Lanchbury, John T Henderson, Nicole Lambert, Paul Parkinson, Ralph L Mcdade, Richard Bryan Riggsbee, S Louise Phanstiel and Walter Phd Gilbert.
View institutional ownership trends for Myriad Genetics
.

Which institutional investors are selling Myriad Genetics stock?

MYGN stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., JPMorgan Chase & Co., Russell Investments Group Ltd., Northern Trust Corp, Credit Suisse AG, Voloridge Investment Management LLC, Guggenheim Capital LLC, and Barclays PLC. Company insiders that have sold Myriad Genetics company stock in the last year include Alexander Ford, Jerry S Lanchbury, and Paul Parkinson.
View insider buying and selling activity for Myriad Genetics
or view top insider-selling stocks.

Which institutional investors are buying Myriad Genetics stock?

MYGN stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Norges Bank, SummerHaven Investment Management LLC, New York State Common Retirement Fund, Nuveen Asset Management LLC, BlackRock Inc., Tudor Investment Corp Et Al, and SummerHaven Investment Management LLC. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, S Louise Phanstiel, and Walter Phd Gilbert.
View insider buying and selling activity for Myriad Genetics
or or view top insider-buying stocks.

How do I buy shares of Myriad Genetics?

Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $27.84.

How much money does Myriad Genetics make?

Myriad Genetics has a market capitalization of $2.09 billion and generates $638.60 million in revenue each year. The company earns $-199,500,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.

How many employees does Myriad Genetics have?

Myriad Genetics employs 2,700 workers across the globe.

What is Myriad Genetics' official website?

The official website for Myriad Genetics is www.myriad.com.

Where are Myriad Genetics' headquarters?

Myriad Genetics is headquartered at 320 WAKARA WAY, SALT LAKE CITY UT, 84108.

How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.